Medical Treatment of Open-angle Glaucoma in 2011

2011 ◽  
Vol 05 (02) ◽  
pp. 123
Author(s):  
Gábor Holló ◽  
Keyword(s):  
Open Angle Glaucoma ◽  
Routine Clinical Practice ◽  
Fixed Dose ◽  
Eye Drops ◽  
Open Angle ◽  
Treatment Intensification ◽  
Dose Combination ◽  
Combined Medication ◽  
Preservative Free

Treatment possibilities for open-angle glaucoma have improved considerably in recent years. Fixed-dose combination eye drops and preservative-free preparations are used increasingly in routine clinical practice, and may reduce the frequency and severity of the medication-related ocular surface problems. Despite this progress, our knowledge of several aspects of the use of combined medication is suboptimal and in many cases treatment intensification or surgery is not introduced in time. To improve the quality of glaucoma care it is useful to review the problematic aspects of treatment.

scholarly journals Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost-Timolol Fixed-Dose Combination Versus Preservative-Free Latanoprost-Timolol Fixed-Dose Combination Therapy: Real-World Experience

2021 ◽  
Author(s):  
Ulrich Thelen
Keyword(s):  
Combination Therapy ◽  
Ocular Hypertension ◽  
Primary Open Angle Glaucoma ◽  
Fixed Combination ◽  
Open Angle Glaucoma ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Open Angle ◽  
Dose Combination ◽  
Preservative Free

Abstract Background: To evaluate the effect of an "escalation" of topical glaucoma therapy by switching form prostaglandin monotherapy to two different prostaglandin-timolol fixed combinations.Methods: 30 patients (60 eyes) with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) were initially treated with the prostaglandin analog latanoprost in a preservative-free formulation. 15 patients each were for 6 months - because of IOP levels considered still too high - treated with preservative-free tafluprost/timolol fixed-dose combination or preservative-free latanoprost/timolol fixed-dose combination therapy. Results: Six months after switching from latanopost monotherapy to preservative-free prostaglandin-timolol combinations, patients being treated with the latanoprost-timolol fixed combination had a mean IOP reduction by 4.16 mm Hg and those treated with the tafluprost-timolol fixed combination a mean IOP reduction by 5.38 mm Hg. Regarding safety and tolerability, there were no issues in the tafluprost-timolol group.Conclusions: Switching from prostaglandin monotherapy to a prostaglandin-timolol fixed combination led to a sufficient IOP lowering in our group of patients. Tolerability of, and satisfaction with, the fixed combination therapies was high.

scholarly journals Preservative-free versus preserved latanoprost eye drops for reducing intraocular pressure: a non-inferiority phase III randomized, multi-center, single-blind, parallel-group controlled trial

2021 ◽  
Vol 9 (4) ◽  
Author(s):  
Panos Theodosiadis ◽  
Anastasios Konstas ◽  
Ioannis Halkiadakis ◽  
Vasiliki Dimera ◽  
Dimitrios Koufakis ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Ocular Hypertension ◽  
Open Angle Glaucoma ◽  
Ophthalmic Solution ◽  
Phase Iii ◽  
Point Estimate ◽  
Eye Drops ◽  
Open Angle ◽  
Parallel Group ◽  
Preservative Free

Background: The aim of this study was to test the non-inferiority of preservative-free (PF) latanoprost 50 μg/mL multi-dose ophthalmic solution versus the marketed benzalkonium chloride (BAK)-preserved latanoprost 50 μg/mL ophthalmic solution in patients with open-angle glaucoma and patients with ocular hypertension. Methods: This was a prospective, national, randomized, multi-center, observer-blind, parallel-group controlled clinical trial. Patients were randomized to receive either PF or BAK-preserved latanoprost once daily for 12 weeks. The primary endpoint was the change in intraocular pressure (IOP) at 8:00 AM in the affected eye between the end of the treatment (week 12) and the baseline (week 0). Secondary measurements were taken at weeks 2 and 6, with IOP being recorded at 8:00 AM, 12:00 PM, and 4:00 PM. Results: A total of 158 patients were included in the per protocol (PP) population (77 in the PF latanoprost treatment arm and 81 patients in the BAK-preserved latanoprost treatment arm). PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP at 8:00 AM in the study eye from the baseline (week 0) to the end of the treatment (week 12). The point estimate of the between-treatment difference was 0.1 mmHg (95% confidence interval: -0.646, 0.847). Mean between-group differences in IOP reduction from the baseline to each of the secondary measurements were also similar between the two treatment arms. The two treatments were well tolerated and had comparable adverse event profiles. Conclusions: PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Both treatments were well tolerated.

Sign in / Sign up

Export Citation Format

Share Document